|
|
Béatrice Jacquelin, Véronique Mayau, Brice Targat, Anne-Sophie Liovat, Désirée Kunkel, Gaël Petitjean, Marie-Agnès Dillies, Pierre Roques, Cécile Butor, Guido Silvestri, Luis D. Giavedoni, Pierre Lebon, Françoise Barré-Sinoussi, Arndt Benecke, Michaela C. Müller-Trutwin
J Clin Invest. 2009;
119(12):3544
doi:10.1172/JCI40093
Abstract |
Full text
| PDF
| Supplemental material

A
frican green monkeys (AGMs) infected with the AGM type of SIV (SIVagm) do not develop chronic immune activation and AIDS, despite viral loads similar to those detected in humans infected with HIV-1 and rhesus macaques (RMs) infected with the RM type of SIV (SIVmac). Because chronic immune activation drives progressive CD4+ T cell depletion and immune cell dysfunctions, factors that characterize disease progression, we sought to understand the molecular basis of this AGM phenotype. To this end, we longitudinally assessed the gene expression profiles of blood- and lymph node–derived CD4+ cells from AGMs and RMs in response to SIVagm and SIVmac infection, respectively, using a genomic microarray platform. The molecular signature of acute infection was characterized, in both species, by strong upregulation of type I IFN–stimulated genes (ISGs). ISG expression returned to basal levels after postinfection day 28 in AGMs but was sustained in RMs, especially in the lymph node–derived cells. We also found that SIVagm induced IFN-α production by AGM cells in vitro and that low IFN-α levels were sufficient to induce strong ISG responses. In conclusion, SIV infection triggered a rapid and strong IFN-α response in vivo in both AGMs and RMs, with this response being efficiently controlled only in AGMs, possibly as a result of active regulatory mechanisms.
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal.
Not all publishers participate in CrossRef, so this information is not comprehensive.
Additionally, data may not reflect the most current citations to this article,
and the data may differ from citation information available from other sources
(for example, Google Scholar, Web of Science, and Scopus).
Total citations by year
in CrossRef
Citations to this article
in CrossRef
(4)
| Title and authors |
Publication |
Year |
Blocking Type I Interferon Production: A New Therapeutic Option to Reduce the HIV-1-Induced Immune Activation
Moritz Ries, Kathrin Pritschet, Barbara Schmidt
|
Clinical and Developmental Immunology
|
2012 |
Characterization of an Effective CTL Response against HIV and SIV Infections
Meritxell GenescĂ
|
Journal of Biomedicine and Biotechnology
|
2011 |
Innate immunity and chronic immune activation in HCV/HIV-1 co-infection
Veronica D. Gonzalez, Alan L. Landay, Johan K. Sandberg
|
Clinical Immunology
|
2010 |
Global genomic analysis reveals rapid control of a robust innate response in SIV-infected sooty mangabeys
Steven E. Bosinger, Qingsheng Li, Shari N. Gordon, Nichole R. Klatt, Lijie Duan, Luoling Xu, Nicholas Francella, Abubaker Sidahmed, Anthony J. Smith, Elizabeth M. Cramer, Ming Zeng, David Masopust, John V. Carlis, Longsi Ran, Thomas H. Vanderford, Mirko Paiardini, R. Benjamin Isett, Don A. Baldwin, James G. Else, Silvija I. Staprans, Guido Silvestri, Ashley T. Haase, David J. Kelvin
|
J. Clin. Invest.
|
2009 |
|